ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
Company Details
- Employees
- 19
- Founded
- -
- Address
- 423 Hindry Ave.,
- Phone
- 8883953370
- in****@****nab.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- imaginab.com
- Keywords
- Antibody engineering and imaging, Personalized medicine, Therapeutic management, Clinical development, PET radiopharmaceuticals, 89Zr-, PET Imaging, Minibody, Biomarker, Immunocology, CD8, T cells, Immunology, Oncology, cancer, CD8 Tracer.
- HQ
- Inglewood, CA
Imaginab Questions
Imaginab's helpline number is 8883953370
Imaginab's website is imaginab.com
Imaginab's LinkedIn profile is https://www.linkedin.com/company/imaginab
Imaginab has
19 employees.
View email and phone details for 19
employees at Imaginab.
Imaginab's industry is
Biotechnology Research
Imaginab's support email address is info@imaginab.com
Imaginab's categories are Biotechnology Research
Imaginab's founding year is 2007
